Stocks
Palisade Bio, Inc.PALI
NASDAQHealthcareBiotechnology$1.20
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oral therapies for gastrointestinal diseases, with a lead candidate targeting ulcerative colitis. Its pipeline focuses on locally acting drugs designed to minimize systemic exposure, and investors track it for its upcoming clinical data readouts and potential partnerships.
52W Range: $1.17-$2.86
Congressional Interest in Palisade Bio, Inc. (PALI)
1 member of Congress has disclosed 2 trades in Palisade Bio, Inc. (PALI), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
2
Sells
0
Who in Congress Is Trading PALI?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-05-21 | JOHN K. DELANEY | buy | $15K-$50K |
| 2012-02-10 | JOHN K. DELANEY | buy | $1K-$15K |